This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (27)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Howard M. Leibowitz, MD; Jimmy D. Bartlett, OD; Richard Rich, MD; Henry McQuirter, OD; Robert Stewart, MD; Kerry Assil, MD

Arch Ophthalmol. 1996;114(8):933-937.

Abstract
Objective
To compare the intraocular pressure (IOP) elevating potential of 1.0% rimexolone and 0.1% fluorometholone alcohol ophthalmic suspensions in patients known to have responded to corticosteroids.

Design
In a double-masked, randomized, single-eye, crossover protocol, corticosteroid responsiveness initially was verified in 40 asymptomatic known steroid responders by challenge with either 0.1% dexamethasone sodium phosphate or 1.0% prednisolone acetate for up to 6 weeks. After a 1-month medication washout, subjects randomly received either rimexolone or fluorometholone for 6 weeks. Medications were again discontinued for 1 month, and subjects then received the alternate drug for 6 weeks.

Results
There was no significant difference between rimexolone and fluorometholone in the number of subjects demonstrating a 10-mm Hg increase in IOP or in the mean number of weeks required to achieve a 10-mm Hg response. Responses occurred in significantly more subjects receiving dexamethasone sodium phosphate (P=.001) or prednisolone acetate (P<.001) and in a significantly shorter interval than in subjects receiving rimexolone.

Conclusions
Rimexolone has a low IOP-elevating potential, comparable to that of fluorometholone and less than that of dexamethasone sodium phosphate and prednisolone acetate.

Author Affiliations
From Boston University School of Medicine, Boston, Mass (Dr Leibowitz); School of Optometry, University of Alabama, Birmingham (Dr Bartlett); Eye Institute of Indiana, Indianapolis (Dr Rich); Eye-Tech, Memphis, Tenn (Dr McQuirter); Houston Eye Associates, Houston, Tex (Dr Stewart); and Anheuser-Busch Eye Institute, St Louis, Mo (Dr Assil). None of the authors has any commercial, proprietary, or financial interest in any of the products described in this article. Dr Leibowitz has occasionally served as a paid consultant to Alcon Laboratories Inc (Fort Worth, Tex).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Caspase-1 Inhibitor Reduces Severity of Pseudomonas aeruginosa Keratitis in Mice
Thakur et al.
IOVS 2004;45:3177-3184.
ABSTRACT | FULL TEXT  

Cut and paste: a no suture, small incision approach to pterygium surgery
Koranyi et al.
Br J Ophthalmol 2004;88:911-914.
ABSTRACT | FULL TEXT  

Ocular-Hypertensive and Anti-inflammatory Response to Rimexolone Therapy in Children
Fan et al.
Arch Ophthalmol 2003;121:1716-1721.
ABSTRACT | FULL TEXT  

Pharmacological Validation of a Feline Model of Steroid-Induced Ocular Hypertension
Bhattacherjee et al.
Arch Ophthalmol 1999;117:361-364.
ABSTRACT | FULL TEXT  

Corticosteroid Therapy of Eye Disease: Fifty Years Later
Raizman
Arch Ophthalmol 1996;114:1000-1001.
ABSTRACT